Ilhan-Mutlu, Aysegül
Puhr, Hannah C. http://orcid.org/0000-0002-7203-8732
Berchtold, Luzia
Zingerle, Linda
Felfernig, Melanie
Weissenbacher, Lisa
Jomrich, Gerd
Asari, Reza
Schoppmann, Sebastian F.
Prager, Gerald W. http://orcid.org/0000-0002-7854-7781
Bergen, Elisabeth S. http://orcid.org/0000-0002-0374-1408
Berghoff, Anna S. http://orcid.org/0000-0001-9379-6797
Preusser, Matthias http://orcid.org/0000-0003-3541-2315
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 4 June 2024
Accepted: 10 August 2024
First Online: 5 September 2024
Declarations
:
: A. Ilhan-Mutlu: participation in advisory boards organized by MSD, Servier, Daiichi Sankyo and BMS, lecture honoraria from Eli Lilly, Servier, BMS, MSD, Astellas and Daiichi Sankyo, local principal investigator for clinical trials sponsored by BMS and Roche, consulting for Astellas and MSD, travel support from BMS, Roche, Eli Lilly and Daiichi Sankyo. H.C. Puhr has received travel support from Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre and Roche and received lecture honoraria from Eli Lilly. G.W. Prager has the following to declare: advisory role/speaker fees: Merck Serono, Roche, Amgen, Sanofi, Lilly, Servier, Taiho, Bayer, Halozyme, BMS, MSD, Celgene, Pierre Fabre, Shire, CECOG, Astra Zeneca. A.S. Berghoff has received research support from Daiichi Sankyo and Roche, honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen, Daiichi Sankyo, and AbbVie. M. Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier. E.S. Bergen, L. Berchtold, L. Zingerle, M. Felfernig, L. Weissenbacher, G. Jomrich, R. Asari and S.F. Schoppmann declare that they have no competing interests.
: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of the Medical University of Vienna (reference number: 1600/2021). The risk of publication of sensitive patient data was minimized by restrictions of data accession and pseudonymized statistical analysis. Due to the retrospective design no separate informed consent was necessary in the scope of this study. This is in line with local ethical standards and was approved by the ethics committee of the Medical University of Vienna (reference number: 1600/2021).